Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$10.75
-0.13 (-1.19%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $19.4M · quality 42.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.8B
P/E
153.6x
↑EV/EBITDA
17.6x
↑ROE
8.2%
↑Gross Margin
67.4%
↑Debt/Equity
1.84
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+1.7%
FCF CAGR
+9.1%
FCF margin
7.2%
FCF / Net income
2.51x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $870.8M · net income $24.9M · FCF $62.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $870.8M | $870.8M | $846.6M | $799.3M | $829.0M |
| Net Income | $24.9M | $24.9M | $42.2M | $25.2M | $-118.5M |
| EBITDA | $171.8M | $171.8M | $155.9M | $147.0M | $20.8M |
| EPS | 0.10 | 0.10 | 0.17 | 0.10 | -0.50 |
| Gross Margin | 67.4% | 67.4% | 66.9% | 67.8% | 69.7% |
| Operating Margin | 13.2% | 13.2% | 9.7% | 4.2% | -2.2% |
| Net Margin | 2.9% | 2.9% | 5.0% | 3.2% | -14.3% |
| Balance Sheet | |||||
| Debt/Equity | 1.84 | 1.84 | 1.35 | 0.66 | 1.05 |
| Current Ratio | 0.92 | 0.92 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $62.5M | $62.5M | $19.4M | $3.9M | $48.1M |
| Returns | |||||
| ROE | 8.2% | 8.2% | 12.3% | 4.2% | -20.6% |
| Valuation | |||||
| P/E | 153.57 | 153.57 | 47.39 | 91.85 | — |
| EV/EBITDA | 17.65 | 17.65 | 14.85 | 17.53 | 99.74 |
| P/B | 8.64 | 8.64 | 5.83 | 3.86 | 3.02 |
| Growth & Yield | |||||
| Revenue Growth | 2.9% | 2.9% | 5.9% | -3.6% | — |
| EPS Growth | -41.8% | -41.8% | 67.1% | 120.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
111.0%
EPS terminal req.
$0.95
Spread vs growth
-152.8%
5Y implied EPS CAGR
62.6%
EPS terminal req.
$1.15
Spread vs growth
-104.4%
10Y implied EPS CAGR
33.7%
EPS terminal req.
$1.86
Spread vs growth
-75.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+17.2%
Start / end P/E
52.6x → 105.9x
EPS bridge
0.17 → 0.10
Residual
-42.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.